Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Colorado BioScience

07:51 EDT 23rd April 2018 | BioPortfolio

Here are the most relevant search results for "Colorado BioScience" found in our extensive news archives from over 250 global news sources.

More Information about Colorado BioScience on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Colorado BioScience for you to read. Along with our medical data and news we also list Colorado BioScience Clinical Trials, which are updated daily. BioPortfolio also has a large database of Colorado BioScience Companies for you to search.

Showing News Articles 1–25 of 72 from Colorado BioScience

Friday 20th April 2018

Weekly Policy Update: Action on Two Bills and Advocacy in DC

UNDER THE GOLD DOME This week, HB18-1135: Extend Advanced Industry Export Acceleration Program passed the Colorado House of Representatives and next week it moves to the Senate. This bill extends the advanced industries export acceleration program to businesses looking to expand and grow their business in international markets. It is an important top proactive bill that CBSA supports for ...

Monday 16th April 2018

Driving Down Drug Costs

Three Solutions to Help Patients and Support Innovators Current proposals under consideration at the Colorado State Legislature propose a simple fix for a complex issue. We agree, patients and their families need access to affordable medicines and health care. However, we believe patients need innovators and policymakers at the federal and state level to and address our health care system...

Friday 13th April 2018

Weekly Policy Update: CBSA Takes Positions on Additional Bills, Transparency News, and China Tariffs

UNDER THE DOME The Colorado BioScience Association took formal positions on three bills this week. With 18 working days left of session we continue to evaluate and make recommendations on legislation being introduced. Outlined below are details on four bills on which CBSA recently took a position. Please connect with us if you'd like to weigh in. CBSA SUPPORTS HB18-1284 - Disclosure of Pr...

Friday 6th April 2018

Weekly Policy Update: CO House Votes on Prescription Drug Price Transparency Bill Monday!

Colorado House Votes next week on Prescription Drug Price Transparency Bill (HB18-1260) CBSA continues to advocate against House Bill 1260, Prescription Drug Price Transparency. The bill could stifle bioscience innovation in Colorado and harm patients. Colorado Bioscience Association (CBSA) and BIO advocate for True Transparency to help patients understand the role of manufacturer

Monday 2nd April 2018

Understanding Bills at the Legislature

Where Do Patients Fit In? Colorado families need access to medicines and health care at affordable prices. That’s why Colorado BioScience Association supports True Transparency. This means considering our complex health care system as a whole to make positive changes for patients and their families. House Bill 1260 (HB18-1260), under consideration by the full House this week, does not con...

Friday 30th March 2018

Weekly Policy Update: Colorado Budget and Forecast, plus a True Transparency update

CO State Budget & March Forecast Transportation, Education, PERA, and opioid addiction are a few of the areas that will receive funding in the $28.9 billion state budget package passed by the Colorado House of Representatives this week. The budget will now go to the CO State Senate where it will be debated over the following week. Every December and March, the state issues an updated budge...

Monday 26th March 2018

How do drug companies determine prices?

The Value of Innovation When you stop in to the pharmacy to pick up a prescription, you may wonder how manufacturers determine the price you pay. You may think the drug maker maintains full control over what you spend. The reality is much more complex. Development times that run more than a decade, billions of dollars invested in research and development and a complex health care system al...

Friday 23rd March 2018

Weekly Policy Update: Advocacy Around Drug Transparency Issues, an Opportunity To Be Heard By the Next Governor, and the Omnibus Spending Bill

This week CBSA testified in opposition to House Bill 1009, Diabetes Drug Pricing Transparency Act 2018. The bill was heard in the House Health, Insurance and Environment Committee and passed on a party line vote. It will now move to House Appropriations. We continue to advocate in opposition and tell our story to legislators that we are dedicated to patients and ensuring people live long...

Monday 19th March 2018

What are Pharmacy Benefit Managers?

PBMs Largely Determine How Much Your Medicines Cost With public policy debate at Colorado’s State Capitol focused on prescription drug price transparency, it’s critical for our decision makers and their constituents to examine all of the players in our complex health care system. One of those players is the Pharmacy Benefit Manager, or PBM. While you may recognize their names, Express Sc...

Friday 16th March 2018

Weekly Policy Update: Continuing the Transparency Advocacy and a Business Guide for the Governor

  CBSA Continues to Advocate in Opposition to House Bill 1260, Prescription Drug Price Transparency As reported last week, House Bill 1260, Prescription Drug Price Transparency passed on a party line vote out of the House Health, Insurance and Environment Committee. We now wait for its hearing in House Appropriations Committee. CBSA and our industry partners are working persisten...

Monday 12th March 2018

Articulus Bio to Present at 6th Annual Venture Summit West Investor Conference

Articulus Bio, LLC, a development-stage orthopedic medical device platform focused on total joint replacement, today announced that Adam B. Rubenstein, Chief Executive Officer, will present at the 6th Annual Venture Summit West investor conference on Wednesday, March 14, 2018, at 10:00 a.m. PST. The conference is being held at the Santa Clara Convention Center in Santa Clara, California. ...

Understanding the Costs of Your Rx

Who Determines What You Pay for Prescription Medicines? When you visit your pharmacy counter to pick up a prescription, do you know who determines the final cost you pay? Many people think it’s one company, the drug manufacturer. It turns out the company that researches, develops and brings innovative drugs to market is just one player in a complex system. How Do Drug Manufacturers Determin...

Friday 9th March 2018

Weekly Policy Update: Prescription Drug Price Transparency

Transparency at the Colorado State Capitol This week CBSA testified in opposition to House Bill 1260, Prescription Drug Price Transparency. The bill was heard in the House Health, Insurance and Environment Committee and passed on a party line vote. It will now move to House Appropriations. We continue to advocate in opposition and tell our story to legislators that we are dedicated to pati...

Monday 5th March 2018

How Do Innovative Medicines Save Lives?

Transforming How We Treat and Cure Diseases We support true transparency, which means working together to provide patients access to affordable medicines. While a few bad actors make headlines, millions of people here in Colorado and around the world benefit from life-saving prescription drugs. Almost everyone has a story: An uncle or aunt with heart disease A friend with cance...

Friday 2nd March 2018

Weekly Policy Update: House Bill 1260 Prescription Drug Transparency, plus the Advamed Fly-In in Washington, D.C.

Urge a NO Vote on HB 1260, Prescription Drug Price Transparency This week CBSA opposed a new bill introduced by the Colorado House that could adversely impact the Colorado bioscience industry, House Bill 1260, Prescription Drug Price Transparency. We need your help to contact your legislator URGING a NO VOTE. The legislation that was originally scheduled to be heard this week in the H...

CSU’s BioMARC Wins HIV Vaccine Manufacturing Project

BioMARC, a non-profit biologics contract development and manufacturing organization (CDMO) owned and operated by Colorado State University (CSU), has won a large new contract with Sumagen Co., Ltd, a Seoul, South Korea based global biotechnology company to scale up their manufacturing process for an innovative new HIV vaccine candidate. The key task of this new contract is to ...

Monday 26th February 2018

What is True Transparency?

Working Together to Provide Access to Affordable Medicines It’s time to start a community conversation about prescription medicines and the out-of-pocket costs for patients. Several bills under consideration at the Colorado state legislature address prescription drug pricing. The Colorado Bioscience sector agrees that patients need access to medicines and health care at costs they can affor...

Cleanroom World Opens Training Center

  Colorado-Based Controlled Environment Supplier Provides Fully-Operational Cleanroom Training Center for Industry Specific Needs Cleanroom World has announced the opening of its on-site training facility. With over thirty years of supporting and supplying controlled environment equipment and materials to the multi-disciplined industry, the need for adequately trained personnel has been r...

Friday 23rd February 2018

Weekly Policy Update: Positions on three bills, true transparency, and a visit to D.C.

UNDER THE DOME The Colorado BioScience Association took formal positions on three bills this week and we continue to evaluate and make recommendations on legislation being introduced. Outlined below are details on the three new bills. Please connect with us if you'd like to weigh in. CBSA SUPPORTS SB18-042 - Concerning the creation of the agricultural workforce development program The bill re...

BIO Business Solutions Introduces Cyber Insurance Coverages through Aon and Chubb

    As a leading life sciences firm, it’s your mission to drive innovation and ensure your people and assets are protected. The pervasiveness of Cyber in day-to-day business operations introduces seriou...

Friday 16th February 2018

Weekly Policy Update: True Transparency and Medicare Stakeholder Input

TRUE TRANSPARENCY CBSA promotes the interests of more than 725 bioscience companies and their 30,000 employees. We work every day to create an innovation-friendly business environment ensuring that as an industry we deliver value to patients and our state’s economy while creating the next generation of treatments and cures. At CBSA we agree that patients need access to medicines and ...

Monday 12th February 2018

Vivaldi Biosciences’ Phase 2 Influenza Vaccine Shows Broad Cross-Protection and Superiority in Nonclinical Study

  FORT COLLINS, Colorado – February 12, 2018 − Vivaldi Biosciences, based at the Research Innovation Center at Colorado State University and Vienna, Austria, today announced that its deltaFLU influenza vaccine shows broad cross-protection against distantly related influenza strains, and superior protection versus a leading licensed vaccine in a recently completed nonclinical study...

Friday 9th February 2018

Weekly Policy Update: Colorado BioScience Association Highlights State's Life-Saving Medical Breakthroughs for Lawmakers

This week we had a successful CBSA Day at the Capitol. At the event we heard from Lieutenant Governor Donna Lynne on her top priorities, outlook on the opioid and substance abuse task force and the future of our state as it relates to healthcare. Lt. Governor’s remarks were a great opportunity for our companies to hear from State leadership and ask top of mind questions. Throughout t...

Friday 2nd February 2018

Friday Policy Updates 2/2/2018

As things continue to be active and heat up over at the Colorado State Capitol, this week the Colorado BioScience Association took formal positions on three bills, while continuing to evaluate and make recommendations on legislation being introduced. Outlined below are further details - and encouragement to reach out to CBSA for your perspective.  CBSA SUPPORTS HB18-1135: Extend Adva...

Friday 26th January 2018

Friday Policy Updates 1/26/2018

UNDER THE DOME The CBSA team will be busy this legislative session working on bills that stand to have a negative impact on our industry, with an anticipated 7 healthcare transparency bills aimed at lowering health care costs. Additionally, CBSA will work on legislation that improves the business, workforce and industry growth strategies in the State. Of the bills introduced to date this s...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks